Top

Published in:

Open Access 01-12-2024 | Metastasis | Research

25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERβ/TNFRSF17 axis

Authors: Mengting He, Wenbo Jiang, Xingkai Li, Hongjin Liu, Hongsheng Ren, Yanliang Lin

Published in: BMC Cancer | Issue 1/2024

Abstract

Lung adenocarcinoma is the main type of lung cancer in women. Our previous findings have evidenced that 25-hydroxycholesterol (25-HC) promotes migration and invasion of lung adenocarcinoma cells (LAC), during which LXR as a 25-HC receptor plays an important role. Estrogen receptor beta (ERβ) is a receptor of 27-hydroxycholesterol that is structurally analogous to 25-HC, but its role in the functional actions of 25-HC remained largely unknown. In this study, we demonstrated that 25-HC treatment triggered ERβ expression in LAC. Knockdown of ERβ inhibited 25-HC-mediated proliferation, migration and invasion, and reduced 25-HC-induced LAC metastasis in vivo. Further investigation revealed that ERβ knockdown restrained the expression of TNFRSF17 (BCMA). In vivo experiments also confirmed that ERβ knockdown blocked 25-HC-induced TNFRSF17 expression. TNFRSF17 knockdown also restrained 25-HC-induced proliferation, migration and invasion. Bioinformatic analysis showed that the levels of ERβ and TNFRSF17 were elevated in lung adenocarcinoma, and were closely related to tumor stages and nodal metastasis status. These results suggested that 25-HC promoted the proliferation and metastasis of LAC by regulating ERβ/TNFRSF17 axis.

Available only for authorised users

Global Burden of Disease, Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, Regional, and National Cancer incidence, mortality, years of Life Lost, Years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2017: a systematic analysis for the global burden of Disease Study. JAMA Oncol. 2019;5:1749–68. https://doi.org/10.1001/jamaoncol.2019.2996CrossRef

Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: a review. Gend Med. 2010;7:381–401. https://doi.org/10.1016/j.genm.2010.10.002CrossRefPubMed

Taioli E, Wynder EL. Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst. 1994;86:869–70. https://doi.org/10.1093/jnci/86.11.869CrossRefPubMed

Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 1989;44:833–9. https://doi.org/10.1002/ijc.2910440515CrossRefPubMed

Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res. 2005;65:1598–605. https://doi.org/10.1158/0008-5472.CAN-04-2694CrossRefPubMed

Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res. 2005;11:7280–7. https://doi.org/10.1158/1078-0432.CCR-05-0498CrossRefPubMed

Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer. 2002;37:153–9. https://doi.org/10.1016/s0169-5002(02)00039-9CrossRefPubMed

Riscal R, Skuli N, Simon MC. Even Cancer cells watch their cholesterol! Molecular cell. (2019) 76: 220–31. https://doi.org/10.1016/j.molcel.2019.09.008. Epub 2019 Oct 2.

Cyster JG, Dang EV, Reboldi A, Yi T. 25-Hydroxycholesterols in innate and adaptive immunity. Nat Rev Immunol. 2014;14:731–43. https://doi.org/10.1038/nri3755. Epub 2014 Oct 17.CrossRefPubMed

10.

Chen L, Zhang L, Xian G, Lv Y, Lin Y, Wang Y. 25-Hydroxycholesterol promotes migration and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun. 2017;484:857–63. https://doi.org/10.1016/j.bbrc.2017.02.003. Epub 2017 Feb 4.CrossRefPubMed

11.

Eibinger G, Fauler G, Bernhart E, Frank S, Hammer A, Wintersperger A, et al. On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment. Exp Cell Res. 2013;319:1828–38. https://doi.org/10.1016/j.yexcr.2013.03.025. Epub 2013 Mar 26.CrossRefPubMedPubMedCentral

12.

Lappano R, Recchia AG, De Francesco EM, Angelone T, Cerra MC, Picard D, et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE. 2011;6:e16631. https://doi.org/10.1371/journal.pone.0016631CrossRefPubMedPubMedCentral

13.

Wang S, Yao Y, Rao C, Zheng G, Chen W. 25-HC decreases the sensitivity of human gastric cancer cells to 5-fluorouracil and promotes cells invasion via the TLR2/NF-kappaB signaling pathway. Int J Oncol. 2019;54:966–80. https://doi.org/10.3892/ijo.2019.4684CrossRefPubMedPubMedCentral

14.

van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8:e446–61. https://doi.org/10.1016/S2352-3026(21)00057-0CrossRefPubMed

15.

Notas G, Alexaki VI, Kampa M, Pelekanou V, Charalampopoulos I, Sabour-Alaoui S, et al. APRIL binding to BCMA activates a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest in liver cells. J Immunol. 2012;189(10):4748–58. https://doi.org/10.4049/jimmunol.1102891CrossRefPubMed

16.

Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103(8):3148–57. https://doi.org/10.1182/blood-2003-06-1984CrossRefPubMed

17.

Li X, Chen H, Zhang L, Chen L, Wei W, Gao S, et al. 27-hydroxycholesterol linked high cholesterol diet to lung adenocarcinoma metastasis. Oncogene. 2022;41:2685–95. https://doi.org/10.1038/s41388-022-02285-yCrossRefPubMedPubMedCentral

18.

Cao Q, Liu Z, Xiong Y, Zhong Z, Ye Q. Multiple Roles of 25-Hydroxycholesterol in Lipid Metabolism, Antivirus Process, Inflammatory Response, and Cell Survival. Oxid Med Cell Longev(2020) 2020: 8893305. https://doi.org/10.1155/2020/8893305

19.

Zhao J, Chen J, Li M, Chen M, Sun C. Multifaceted functions of CH25H and 25HC to modulate the lipid metabolism, Immune responses, and broadly antiviral activities. Viruses. 2020;12:727. https://doi.org/10.3390/v12070727CrossRefPubMedPubMedCentral

20.

Xu H, Zhou S, Tang Q, Xia H, Bi F. Cholesterol metabolism:new functions and therapeutic approaches in cancer. Biochim et Biophys acta Reviews cancer. 2020;1874:188394. https://doi.org/10.1016/j.bbcan.2020.188394CrossRef

21.

Liu Y, Wei Z, Ma X, Yang X, Chen Y, Sun L, et al. 25-Hydroxycholesterol activates the expression of cholesterol 25-hydroxylase in an LXR-dependent mechanism. J Lipid Res. 2018;59:439–51. https://doi.org/10.1194/jlr.M080440CrossRefPubMedPubMedCentral

22.

Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007;13:1185–92. https://doi.org/10.1038/nm1641CrossRefPubMed

23.

Abdalkareem Jasim S, Kzar HH, Haider Hamad M, Ahmad I, Al-Gazally ME, Ziyadullaev S, et al. The emerging role of 27-hydroxycholesterol in cancer development and progression: an update. Int Immunopharmacol. 2022;110:109074. https://doi.org/10.1016/j.intimp.2022CrossRefPubMed

24.

Ali G, Donati V, Loggini B, Servadio A, Dell’Omodarme M, Prati MC, et al. Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol. 2008;39:1465–73. https://doi.org/10.1016/j.humpath.2008.02.011CrossRefPubMed

25.

Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127:3225–36. https://doi.org/10.1182/blood-2016-01-691162CrossRefPubMedPubMedCentral

26.

Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–60. https://doi.org/10.1158/1078-0432.CCR-12-2422CrossRefPubMedPubMedCentral

27.

Zhang M, Zhu K, Pu H, Wang Z, Zhao H, Zhang J, et al. An Immune-related signature predicts survival in patients with lung adenocarcinoma. Front Oncol. 2019;9:1314. https://doi.org/10.3389/fonc.2019.01314CrossRefPubMedPubMedCentral

Title: 25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERβ/TNFRSF17 axis
Authors: Mengting He
Wenbo Jiang
Xingkai Li
Hongjin Liu
Hongsheng Ren
Yanliang Lin
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Metastasis
Estrogens
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12227-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR

Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes

Correction: Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma

NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers

The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung

Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer